Can Adding a Healing Cream Help Treat Fungal Skin Infections Better

A randomized, open label, prospective investigator initiated interventional study to understand the effects of addition of broad-spectrum antimicrobial skin healing cream (Silversol plus coconut oil plus vitamin E plus Hyaluronic acid) as an adjuvant to an antifungal agent in the management of superficial skin fungal infections. - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2025/12/099526

Enrollment

100

Registered

2025-12-19

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L089- Local infection of the skin and subcutaneous tissue, unspecified

Interventions

Intervention1: Silversol plus: Silversol plus coconut oil plus vitamin E plus Hyaluronic acid) as an adjuvant to an antifungal agent in the management of superficial skin fungal infections.Like topica

Eligibility

Inclusion criteria

Inclusion criteria: Age between 18 (Completed) and 70 yrs Positive for KOH test Able to comply to the prescribed therapy Able to give informed consent

Exclusion criteria

Exclusion criteria: Patient with a known history or clinical evidence of severe cardiac, renal, or hepatic disease (in case of oral itraconazole is prescribed) Pregnant or lactating women (in case of oral itraconazole is prescribed) Treatment with any antipruritic medication including antihistamine within previous 72 hours Systemic antibiotics in the previous 2 weeks Corticosteroid or immunosuppressant in the past 6 weeks Any investigational drug in the previous 3 months

Design outcomes

Primary

Measure	Time frame
A total of 100 patients (50 per arm) with superficial fungal infections (Tinea cruris, Tinea corporis) will be recruited together for both arms.Primary efficacy will be determined by clinical and mycological assessment of lesion at baseline and at end of treatment (EOT) phase. For clinical cure the following signs and symptoms will be assessed: erythema, pruritus, and scaling. Each parameter will be measured on 4-point scale Timepoint: Baseline visit (Visit 1): Week 1 Follow-up 1 (Visit 2): End of week 4 Follow-up 2 (Visit 3): End of week 10 Follow-up 3 (Visit 4): End of week 12	—

Measure

Time frame

A total of 100 patients (50 per arm) with superficial fungal infections (Tinea cruris, Tinea corporis) will be recruited together for both arms.Primary efficacy will be determined by clinical and mycological assessment of lesion at baseline and at end of treatment (EOT) phase. For clinical cure the following signs and symptoms will be assessed: erythema, pruritus, and scaling. Each parameter will be measured on 4-point scale Timepoint: Baseline visit (Visit 1): Week 1 Follow-up 1 (Visit 2): End of week 4 Follow-up 2 (Visit 3): End of week 10 Follow-up 3 (Visit 4): End of week 12

—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Mitaxari Hugar

Karnataka Medical college

drmita333@gmail.com9885712333

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026